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Mobile medical applications (mHealth), music, and video games are being developed and
tested for their ability to improve pharmacotherapy outcomes and medication adherence.
Pleiotropic mechanism of music and gamification engages an intrinsic motivation and
the brain reward system, supporting therapies in patients with neurological disorders,
including neuropathic pain, depression, anxiety, or neurodegenerative disorders. Based on
accumulating results from clinical trials, an innovative combination treatment of epilepsy
seizures, comorbidities, and the medication non-adherence can be designed, consisting
of antiepileptic drugs and disease self-management software delivering clinically bene-
ficial music. Since creative elements and art expressed in games, music, and software
are copyrighted, therefore clinical and regulatory challenges in developing copyrighted,
drug–device therapies may be offset by a value proposition of the exclusivity due to the
patent–independent protection, which can last for over 70 years. Taken together, develop-
ment of copyrighted non-pharmacological treatments (e-therapies), and their combinations
with pharmacotherapies, offer incentives to chronically ill patients and outcome-driven
health care industries.
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INTRODUCTION
Mobile medical applications (mHealth apps) emerge as daily com-
panions to help patients, clinicians, and pharmacists (1–10). There
is a growing number of self-management applications including
those for chronic pain (11, 12), asthma (13), or mental health
(14, 15). One example of an FDA-cleared mobile therapy is Blue-
Star®, the clinical and behavioral self-management platform for
patients with type 2 diabetes, which was shown to improve con-
trol of glucose blood levels (16–18). Mobile medical applications
cleared by the FDA range from diagnostic and monitoring plat-
forms to a sound therapy or interactive medication reminders (19).
The FDA intends to exercise enforcement discretion for mobile
medical applications, which aim to help patients with disease self-
management or medication adherence, while those intended to
perform medical device functions, may require approval or clear-
ance (2). The exponential growth of mobile medical applications
has resulted in a lag of reports from larger scale, randomized
controlled trials (RCTs) to support their clinical utilities (3, 20).
Interactive technologies targeting healthy behaviors and ther-
apy outcomes include video games (21). Clinical utility of serious
video games (e-therapies or therapeutic games) has been studied
in patients with various chronic conditions including depression,
Abbreviations: AEDs, antiepileptic drugs; FDA, Food and Drug Administration;
IP, intellectual property; NSAIDS, non-steroidal anti-inflammatory drugs; PMA,
premarket approval; RCTs, randomized controlled trials.
Parkinson’s disease, asthma, diabetes, cancer, or stroke (22–26).
Table S1 in Supplementary Material provides examples of mobile
apps and games for the treatment of depression, anxiety, demen-
tia, pain, attention deficit hyperactivity disorder (ADHD), and
cerebral palsy. One example of a serious video game is “Re-
Mission,” a game specifically designed for cancer patients and
shown to improve behavioral outcomes, cancer-related knowl-
edge, and medication adherence during chemotherapy in ado-
lescent patients with acute leukemia, lymphoma, and soft-tissue
sarcoma (27, 28). In RCTs, playing video games was found to
be clinically effective in treating depression (25, 29). The use of
video games to modulate the brain neuroplasticity also improved
age-related neuronal deficits and enhanced cognitive functions
in older adults (30). Video games are explored as a preventive
medicine strategy against HIV infections (31), or obesity (32).
Fun and game-based principles (gamification) in serious video
games are important elements when targeting intrinsic motiva-
tion to improve health behaviors (21). In 2014, the FDA cleared
a motion-capture video game, developed by Jintronix as a reha-
bilitation system for stoke patients, or those with traumatic brain
injury.
Music has been applied as a non-pharmacological treat-
ment mainly for neurological conditions. The pleiotropic nature
of music is mediated by neurochemical changes in the brain,
endocrinological, and immune systems (33–35). A therapeutic
potential of music to treat psychiatric disorders was recently
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reviewed (33). Recent studies show clinical applications of music
for epilepsy patients (36, 37), including listening to the Mozart
K.448 sonata, which was shown to reduce frequency of epilepti-
form discharges (38–43), and to reduce seizure frequencies (40,
43, 44). Music-supported therapies include indications such as
pain (45–48), stroke (49, 50), dementia (51, 52), depression (53),
or anxiety (54, 55). A therapeutic music video intervention was
shown to improve resilience in cancer patients being treated with
hematopoietic stem cells (56). Given popularity and convenience
of listening to music, this non-pharmacological treatment can be
easily incorporated into mobile medical applications.
Over the last decade, it has been recognized that a significant
number of patients with chronic diseases fail to take medications
as prescribed (57, 58). Medication non-adherence is considered as
a serious global health care problem (59). While clinical aspects
of medication adherence are studied, economic costs of medica-
tion non-adherence are estimated as $100–290 billion per year in
additional medical spending paid by the US health care (57) and
$564 billion in lost revenues of the global pharmaceutical industry
(60). Current strategies to improve medication adherence include
less frequent dosing, extended-release formulations, novel drug
delivery devices, providing external incentives, or support-based
interventions. Medication non-adherence is a patient behavioral
aspect associated with all chronic diseases. Health care industry
is embracing gamification and electronic platforms in patient
care (61). Clinical studies of mobile medical applications, seri-
ous video games, or music show their promise as tools to improve
therapy outcomes, disease self-management, or medication adher-
ence for chronically ill patients (Figure 1A). This article dis-
cusses opportunities for creating and clinical development of
non-pharmacological treatments, which can be integrated into
specific combination therapies for chronic diseases.
INTEGRATING GAMIFICATION AND MUSIC INTO
THERAPIES – DOPAMINERGIC CONNECTIONS
FDA-cleared mobile and video game therapies, such as BlueStar®
and Jintronix Rehabilitation System, show new opportunities to
integrate drugs with devices, thereby bridging pharmacothera-
pies with disease self-management. Figure 1B shows an example
of pharmacotherapy in combination with a mobile platform for
the treatment of diabetes. Since studies encourage clinical use of
music for pain relief (48, 62, 63), parallel needs for more per-
sonalized treatments of neuropathic pain and for improving pain
relief (64) can be addressed by a combination of an appropri-
ate analgesic and pain self-management platforms with music
and games for pain relief. Therapeutic interactive voice response
has been shown to reduce use of opioids and non-steroidal anti-
inflammatory drugs (NSAIDs) (65). Cancer patients may benefit
from combining chemotherapy with a serious video game, such
as “Re-Mission” (27, 28) or the Patient Empowerment Exercise
Video Game (22) which target comorbidities including depres-
sion, anxiety, or fatigue. Gamification is a tool to engage intrinsic
motivation using such features as choice and decision-making,
levels and challenge, fantasy and curiosity (66). Therapeutic video
games and self-acquired rewards engage the brain reward sys-
tem in active players (67, 68), therefore integrating gamification
into self-management platforms is also useful for motivating and
FIGURE 1 | Examples of drug–device interfaces created by mobile
medical applications, serious video games, or music. (A) Electronic
devices are used to provide music, games, and mobile medical applications,
while also becoming delivery systems for disease self-management
platforms. (B) An example of combining pharmacotherapies with medical
devices for the treatment of diabetes. Mobile therapies, such as BlueStar®,
can support disease-specific, healthy behaviors of a patient, and remind
about taking prescribed medications on-time.
rewarding patients while learning and reinforcing disease-specific
healthy habits.
Studies on physiological effects of music and games begin to
indicate multiple effects on the nervous and endocrine systems,
including music-induced modulation of various neurotransmit-
ters and hormones (34, 35). An overlapping mechanism of gam-
ing and music includes activation of the mesolimbic system and
dopaminergic neurotransmission in the brain (67–72). Game- or
music-evoked dopamine release involving dopamine D2 receptors
was shown by positron emission tomography using 11C-labeled
raclopride (69, 71). Table S2 in Supplementary Material provides
examples of functional magnetic resonance imaging (fMRI) stud-
ies aimed to elucidate music or games mechanism of actions. Both
gaming and music activate nucleus accumbens in the mesolim-
bic reward circuitry, as well as parts of prefrontal cortex (67, 68,
72, 73). Mesolimbic dopamine plays important roles in learning
and motivation (74, 75), thus activation of the dopaminergic sig-
naling by therapeutic games or/and tailored music can facilitate
behavioral and pharmacological interventions in patients. Tar-
geting the dopamine system by playing video games improved
symptoms in schizophrenia patients (76), whereas clinical stud-
ies of games for depression (25) or Parkinson’s disease (24, 77),
encourage similar strategies for migraines or addiction. Taken
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together, the dopaminergic mechanisms of music and games offer
opportunities for coupling the pleasurable brain reward system
with intrinsic motivation and the formation of healthy habits,
resulting in unique disease self-management platforms. Given
pleiotropic effects of music and games, mechanism-based com-
binations of these non-pharmacological treatments with specific
drugs can improve therapy outcomes for various neurological
diseases.
REDEFINING A COMBINATION THERAPY FOR EPILEPSY
Designing innovative drug–device combination therapies can be
illustrated using the treatment of epilepsy. Managing epilepsy
is challenging due to: (i) significant resistance to antiepileptic
drugs (AEDs), (ii) compromised medication adherence, and (iii)
significant prevalence of comorbidities, such as anxiety or depres-
sion (78). Despite many AEDs approved for the treatment of
epilepsy (Figure 2A), estimated 25–40% of patients with epilepsy
are refractory to current AEDs (79). An approximate 50–60%
medication adherence rate among epilepsy patients results in
increased risks of seizures and mortality (80–82), while the main
comorbidity, depression, is also difficult to treat with antide-
pressant drugs (83). To help epilepsy patients with disease self-
management, currently available mobile devices include a Smart-
Watch, which is capable of detecting movements associated with
seizures, as well as mobile applications helping to self-report and
record seizures, manage medications, or learn more facts about
epilepsy.
Accumulating clinical evidence suggests that listening to the
Mozart’s K.448 results in reduction of generalized and focal
seizures in epilepsy patients (36, 37). The K.448 was also effective
in reducing seizure frequencies in children with pharmacoresis-
tant epilepsy (84), and in patients following their first unpro-
voked seizures (43). Using simultaneous electroencephalogram
and electrocardiogram recordings, the reduction of epileptiform
discharges by K.448 and K.545 was shown to be accompanied by
activation of the parasympathetic system (42). While an anticon-
vulsant mechanism of action for audiogenic stimulation remains
unknown, reports also suggest a role of mirror neurons or/and
neurotransmitters pathways including the dopaminergic system
(36, 37). Genetic, pharmacological, and imaging studies support
the dopamine signaling in epilepsy and epileptogenesis, including
D2 receptors (85–88).
To improve pharmacotherapy, manage comorbidities and med-
ication adherence for epilepsy patients, the drug–device combina-
tion therapy can include a specific AED and a matching medical
device delivering non-pharmacological elements (Figure 2B). The
most apparent non-pharmacological component could be music,
which reduces seizures [such as the Mozart’s K.448 or K.545
(41)]. To treat symptoms of depression or anxiety, often expe-
rienced by epilepsy patients, the self-management platform can
include a game comprising cognitive behavioral therapy elements
(29), or even a combination of music and games as musical
games. Such platforms may also help manage seizure-precipitating
stress by modulating cortical responses (89). Noteworthy, a long-
term stimulation of nucleus accumbens can decrease seizure
severity (90), while integrating music into the treatments of
FIGURE 2 | Integrating antiepileptic drugs into a copyrighted
combination therapy for the treatment of epilepsy. (A) Examples of
generic antiepileptic drugs. (B) Designing an integrated combination
therapy consisting of antiepileptic drugs and copyrighted
non-pharmacological components delivered by an electronic device. While
antiepileptic drugs and music can treat epileptic seizures, a
self-management digital platform can include specifically designed games
for the treatment of depression or anxiety.
epilepsy comorbidities was recently emphasized (91). Additional
non-pharmacological components delivered by the medical device
can include medication adherence reminders and other features
to self-report and track seizures. This integrated treatment may
appeal to pediatric epilepsy patients, since non-adherence to AEDs
within the first 6 months significantly affects long-term rates of
becoming seizure-free (92).
Creating therapeutic music to reduce epileptic seizures extends
to translational research, since music can be subject to preclinical
screening [for example, in such indications as addiction (93)]. In
animal testing, exposure to the Mozart K.448 resulted in: (i) reduc-
tion of spontaneous absence seizure and high-voltage rhythmic
spike discharges in Long Evans rats (94), (ii) increased dopamine
levels in rat brains (95), and (iii) decreased corticosterone (95, 96).
Positive effects of the K.448 music on spatial–temporal learning
were reported for rats and mice (97–99). Since clinical data suggest
that K.448 can reduce seizures in patients with refractory epilepsy
(84), studies on interactions between K.448 and AEDs in animal
models of epilepsy may help to elucidate the mechanism of action
of K.448 while increasing the potency of the AEDs. Comparing
preclinical and clinical effects of music in other medical indica-
tions, such as depression, anxiety, addiction, or neurodegenerative
disorders may validate the translational research for using specific
auditory stimulations with drugs.
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COPYRIGHTS AS INCENTIVES FOR CREATING
NON-PHARMACOLOGICAL TREATMENTS
An incentive for creating and clinical development of non-
pharmacological therapies can be their copyrighted works, which
are protected by the intellectual property (IP) law. Unlike patents
protecting ideas, copyright protects the expression of an idea found
in creative elements and art found in digital media, software, elec-
tronic games, and music. In the US, the Copyright Act of 1976
offers the benefit a long-term protection lasting not less than
70 years, and up to 120 years. Copyright protection is automatic
as soon as it is created, although a copyright registration offers
legal advantages in case of any future infringements. Furthermore,
copyright is recognized and protected in most countries under
national and international law through the Universal Copyright
Convention and the Berne Convention which the US joined as a
member in 1955 and 1989, respectively.
In a web-based era, developing games or music intended for
clinical use create opportunities for “off-label” uses, whereas clas-
sical music which exists in public domain (such as Mozart’s K.448
or K.545 sonatas) presents the exclusivity challenge. Re-recording
of specific pieces of classical music may offer recording copyrights,
while re-composing and modifying individual pieces of public-
domain music intended for clinical development may offer an
additional level of protection before evaluating therapeutic claims.
The copyright protection for the music created, re-composed, and
recorded “for hire” can last 120 years. Clinically validated music
can be used as a “stand-alone” non-pharmacological therapy, or
can be integrated into disease self-management digital platforms
or therapeutic games (Figure 2B). The Digital Millenium Copy-
right Act from 1998 is the law protecting copyrighted art and
works used in digital media against infringement and piracy. In
contrast to music, electronic and video games pose complex copy-
right challenges due to multiple components of art involved in
digital technologies (100).
OPPORTUNITIES AND CHALLENGES OF THE COPYRIGHTED
COMBINATION THERAPIES
Using mobile applications, playing electronic games, or listening
to music are daily practices of many patients taking medica-
tions. As mentioned earlier, games and music target intrinsic
motivation and the reward system, becoming useful “personal-
ized medicine” tools to improve patient compliance with their
prescribed pharmacotherapies. For chronically ill patients at risk
for medication non-adherence, gamification strategies are alter-
natives to providing external incentives to reinforce taking drugs
as prescribed, given that patient motivation may decrease once
incentives are discontinued (101). Combination of pharmacother-
apy and gamification can improve treatments for chronic diseases
with inflammatory components (such as rheumatoid arthritis),
which can be lessen by behavioral changes and self-management
platforms (102). Given advances in genomics, individuals carry-
ing mutations in susceptibility genes for chronic diseases may
benefit from non-pharmacological and behavioral interventions.
In addition to encouraging development of preventive medicine
strategies, copyrights can also provide incentives to create innov-
ative treatments for rare genetic disorders, for example epileptic
encephalopathies.
Since medication non-adherence affects approximately half of
the prescribed therapeutics for chronic disorders, drug discovery
and clinical development efforts will benefit from applications of
the copyrighted combination therapies due to integration of phar-
macotherapy outcomes and medication adherence. This aspect
becomes important when translating discoveries of new molec-
ular targets into combination therapies: for example, the treat-
ment of epilepsy emphasize needs for network-based polyphar-
macies (103). Copyrighted therapies may also encourage clinical
development of new combination therapies with clinically ben-
eficial compounds existing in public domain (e.g., curcumin),
due to the IP exclusivity under the premarket approval (PMA)
application. Copyrighted combination products may appeal to
developing therapies for neurodegenerative diseases. For exam-
ple, having 70 years protection of the copyrighted combination
therapy for the Alzheimer disease would facilitate balancing deci-
sions between clinical and business objectives related to lengthy
clinical trials. Pharmaceutical industry is recognizing both oppor-
tunities and challenges in applying mobile medical applications
and gamification in patient care (104, 105). Since changing patent
guidelines can affect drug discovery efforts (106), copyrights can
provide incentives to transform generic drugs into innovative
treatments of chronic diseases with improve medication adherence
and outcomes.
Herein, it is prudent to emphasize challenging times for the
regulatory agencies and for those who seek approval/clearance of
mobile medical applications and their combinations with phar-
macotherapies (1, 107). Integrating drugs with devices is com-
monly associated with combination products such as pen injectors
and insulin, transdermal patches, drug-eluting stents, or drug
creams with light sources (108, 109). The long-term prospects
of the copyrighted combination therapies include becoming
the combination products. For example, given advancements in
medical technologies at the interface of drugs and devices, the
FDA established the Office of Combination Products (110, 111).
Efforts to reach PMA applications for the copyrighted combi-
nation products may be incentivized by the long-term exclusiv-
ity of specific medical treatment due to the copyright protec-
tion. Creation, translational research, and clinical validation of
copyrighted non-pharmacological treatments is a long and chal-
lenging frontier, requiring cross-technological interactions among
pharmaceutical-biotech companies, electronic and mobile devices,
and those providing the creative works such as software, video
games, or music.
Clinical development of the non-pharmacological therapies
like therapeutic games or music, and their combinations with the
pharmacotherapies, carry inherent risks related to safety (adverse
effects) and efficacy (tolerance, addiction). Developing tolerance
to non-pharmacological treatments is unknown, whereas addic-
tive properties of gaming can be addressed by appropriate design
features. Current understanding of mechanisms of musicogenic
seizures and photosensitive epilepsy can facilitate designing music
and games to avoid proconvulsant properties. Incorporation of
features such as patient preference to have choices in selecting
music for the therapy is offset by unknown variables in response
to music due to differences in a patient genetics and personal-
ity [for example individual responses to music for pain treatment
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were reported (63)]. Large-scale RCTs will test therapeutic utility
of non-pharmacological treatments and their combinations with
drugs, and will advance clinical knowledge and design of such
innovative treatments for neurological and other chronic medical
conditions.
CONCLUSION
Taken together, creating and developing copyrighted music,games,
and medical software to be combined with pharmacotherapies
provides an opportunity to deliver novel treatments for patients
with neurological and other chronic diseases. Neuroscience-
centered, innovative drug–device platforms can facilitate delivery
of more personalized and integrated treatments of the target dis-
ease and associated comorbidities, resulting in improved therapy
outcomes and medication adherence. Mechanism-based combi-
nations of pharmacotherapies with non-pharmacological treat-
ments offer win–win solutions for all health care stake-holders.
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